Catheter Precision Inc. Files S-1/A Amendment

TL;DR

Catheter Precision (CPCI) filed an S-1/A, updating its registration. Formerly Ra Medical Systems.

AI Summary

Catheter Precision, Inc. filed an S-1/A amendment on June 14, 2024, related to its registration statement (No. 333-279930). The company, formerly known as Ra Medical Systems, Inc. until September 8, 2017, is incorporated in Delaware and operates in the Surgical & Medical Instruments & Apparatus sector. Its principal executive offices are located in Fort Mill, SC.

Why It Matters

This filing indicates ongoing regulatory activity for Catheter Precision, Inc., which could impact its financial reporting and public trading status.

Risk Assessment

Risk Level: low — This is a routine amendment to a registration statement, not indicating immediate financial distress or significant new risks.

Key Numbers

• 333-279930 — SEC File Number (Registration number for the filing)

Key Players & Entities

• Catheter Precision, Inc. (company) — Registrant
• 333-279930 (registration_number) — SEC Registration Number
• June 14, 2024 (date) — Filing Date
• Ra Medical Systems, Inc. (company) — Former Company Name
• September 8, 2017 (date) — Date of Name Change
• David Jenkins (person) — Executive Chairman and CEO

FAQ

Key Financial Figures

• $0.0001 — common stock (the "Shares" ), par value $0.0001 per share, of Catheter Precision, Inc.,
• $0.5464 — at an assumed public offering price of $0.5464 per share, based on the last sale price
• $0 — n stock is sold in this offering, minus $0.0001, and each Pre-Funded Warrant will
• $1,000,000 — est in purchasing an aggregate of up to $1,000,000 of Common Stock in this offering at the
• $15.1 billion — Scientific Corp. and is estimated to be $15.1 billion by 2028 (CAGR of 13.0%). Population gro
• $3.5 billion — atheter ablation market was larger than $3.5 billion in 2022 and is estimated to grow to $14
• $14.5 billion — ion in 2022 and is estimated to grow to $14.5 billion by 2032 (13.5% CAGR). This market inclu

Filing Documents

• rmed_s1.htm (S-1/A) — 635KB
• rmed_ex231.htm (EX-23.1) — 2KB
• rmed_ex232.htm (EX-23.2) — 3KB
• rmed_s1img9.jpg (GRAPHIC) — 4KB
• rmed_s1img17.jpg (GRAPHIC) — 4KB
• rmed_s1img16.jpg (GRAPHIC) — 23KB
• rmed_s1img15.jpg (GRAPHIC) — 7KB
• rmed_s1img14.jpg (GRAPHIC) — 35KB
• rmed_s1img13.jpg (GRAPHIC) — 5KB
• rmed_s1img12.jpg (GRAPHIC) — 8KB
• rmed_s1img10.jpg (GRAPHIC) — 3KB
• 0001654954-24-007750.txt ( ) — 765KB

RISK FACTORS

RISK FACTORS 17 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 23 DIVIDEND POLICY 24

USE OF PROCEEDS

USE OF PROCEEDS 25

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 28

UNDERWRITING

UNDERWRITING 29 LEGAL MATTERS 33 EXPERTS 33 WHERE YOU CAN FIND ADDITIONAL INFORMATION 33 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 34 Table of Contents ABOUT THIS PROSPECTUS We urge you to read carefully this prospectus, together with the information incorporated herein by reference as described under the heading " Where You Can Find Additional Information " before buying any of the securities being offered. You should rely only on the information contained or incorporated by reference in this prospectus or in any free writing prospectus. We and the underwriter have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus may only be used where it is legal to offer and sell Shares of our common stock and other securities. If it is against the law in any jurisdiction to make an offer to sell these Shares and other securities, or to solicit an offer from someone to buy these Shares and/or other securities, then this prospectus does not apply to any person in that jurisdiction, and no offer or solicitation is made by this prospectus to any such person. You should assume that the information appearing in this prospectus or in any applicable free writing prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or of any sale of common stock or other securities. Our business, financial condition, results of operations and prospects may have changed since such date. Information contained on our website is not a part of this prospectus. A prospectus supplement may add to, update or change the information contained in this prospectus. You should read both this prospectus and any applicable prospectus supplements together with additional information described below under the heading " Where You Can Find Additional Information ." This p

View Full Filing

View this S-1/A filing on SEC EDGAR